Biotechnology News

REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar...

Company announcement no. 40 - 2620 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Gesynta Pharma completes enrollment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis more than three months ahead of schedule

Dose-related clinical activity: Week 12 clinical remission of 23.1% (3/13) in higher-dose Cohort 2 vs. 11.4% (4/35) in lower-dose Cohort 138.9% (7/18) of participants with a Day 29 trough...

 Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates Allschwil,...

Zu den Highlights zählen Vorträge zu pädiatrischen Daten aus dem Expanded Access Program mit Fosmanogepix sowie zur Wirksamkeit dessen aktiven Bestandteils Manogepix gegen Candida-auris-Isolate ...

L’étude sponsorisée par des chercheurs et financée par l’Institut National du Cancer (INCa) atteint le critère de jugement principal d’efficacité préspécifié, avec une survie globale à 12 mois de 61,3...

Eine vom französischen Nationalen Krebsinstitut (INCa) finanzierte, von Forschern initiierte Studie erfüllt das vorab festgelegte primäre Wirksamkeitskriterium mit einer 12-Monats-Gesamtüberlebensrate...

Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the...

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the...